pmid	doi	year	title	Hugo_Symbol
32393046	10.1080/09603123.2020.1757043	2022	The expression of microRNAs and exposure to environmental contaminants related to human health: a review.	BCL6
33779481	10.1080/01676830.2021.1904426	2022	Double-hit and triple-hit high-grade B-cell lymphoma of the ocular adnexa.	BCL6
34180720	10.1177/10668969211027409	2022	Aggressive Cyclin D1 Negative Blastoid Variant Mantle Cell Lymphoma-A Case Report.	BCL6
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	BCL6
34374890	10.1007/s12029-021-00662-6	2022	Primary ALK-Positive Large B Cell Lymphoma of Pancreas.	BCL6
34392269	10.1097/PAS.0000000000001750	2022	Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.	BCL6
34456240	10.1097/PAI.0000000000000967	2022	Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.	BCL6
34519021	10.1111/bjh.17815	2022	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.	BCL6
34559466	10.1111/ijlh.13709	2022	Discordant high-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a pericardial effusion.	BCL6
34601504	10.1038/s41379-021-00938-z	2022	Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation.	BCL6
34608246	10.1038/s41379-021-00909-4	2022	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.	BCL6
34617271	10.1111/bjh.17874	2022	Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.	BCL6
34637146	10.1111/his.14585	2022	EBV<sup>+</sup> high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study.	BCL6
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	BCL6
34698964	10.1007/s10637-021-01196-1	2022	FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells.	BCL6
34707034	10.3960/jslrt.21017	2022	Clinicopathological analysis of diffuse large B-cell lymphoma lacking surface immunoglobulin light chain restriction on flow cytometry.	BCL6
34727403	10.1111/pin.13182	2022	AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	BCL6
34727830	10.1080/10428194.2021.1998480	2022	Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma.	BCL6
34774129	10.1016/j.str.2021.10.010	2022	Structural basis of Apt48 inhibition of the BCL6 BTB domain.	BCL6
34788750	10.1159/000519074	2022	Application of Hans Algorithm for Subcategorization of Diffuse Large B-Cell Lymphoma in Fine-Needle Aspiration Biopsy Cytology.	BCL6
34788985	10.3324/haematol.2021.279631	2022	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing.	BCL6
34809978	10.1016/j.fertnstert.2021.09.036	2022	B-cell lymphoma 6 expression is not associated with live birth in a normal responder in vitro fertilization population.	BCL6
34842019	10.1080/10428194.2021.2008383	2022	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?	BCL6
34861697	10.1182/bloodadvances.2021006156	2022	Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.	BCL6
34907996	10.1097/PAS.0000000000001852	2022	Human Germinal Center-associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma.	BCL6
34910327	10.1111/jop.13269	2022	Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases.	BCL6
34917911	10.1016/j.jhepr.2021.100386	2022	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis.	BCL6
34951009	10.1111/bjh.17971	2022	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.	BCL6
34990752	10.1016/j.canlet.2021.12.035	2022	An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.	BCL6
35036912	10.1177/2632010X211070774	2022	Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow.	BCL6
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	BCL6
35046056	10.1158/1078-0432.CCR-21-3617	2022	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.	BCL6
35067515	10.1097/PAS.0000000000001828	2022	Composite Classic Hodgkin Lymphoma and Follicular Lymphoma: A Clinicopathologic Study of 22 Cases With Review of 27 Additional Cases in the Literature.	BCL6
35091546	10.1038/s41420-022-00833-9	2022	Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.	BCL6
35152630	10.3760/cma.j.cn112151-20210826-00604	2022	[Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].	BCL6
35183824	10.1016/j.prp.2022.153804	2022	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.	BCL6
35220171	10.1016/j.prp.2022.153812	2022	Prognostic value of Bcl2 and Bcl6 in primary cutaneous large B-cell lymphoma: A systematic review and meta-analysis.	BCL6
35256863	10.2147/CMAR.S345745	2022	MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP.	BCL6
35277463	10.1136/jitc-2020-002029corr1	2022	Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	BCL6
35297566	10.1111/pin.13223	2022	Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.	BCL6
35303910	10.1186/s13045-022-01249-9	2022	Altered pathways and targeted therapy in double hit lymphoma.	BCL6
35308723	10.7759/cureus.22023	2022	Conjunctival Pediatric-Type Follicular Lymphoma in a Young Male: A Case Report and Literature Review.	BCL6
35327381	10.3390/biomedicines10030579	2022	Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma.	BCL6
35357654	10.1007/s13402-022-00663-y	2022	BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.	BCL6
35371331	10.7150/jca.69639	2022	Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma.	BCL6
35414839		2022	Primary ovarian Burkitt lymphoma: report of a case and review of literature.	BCL6
35436984	10.1038/s41419-022-04812-x	2022	B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36.	BCL6
35444774	10.4084/MJHID.2022.018	2022	TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.	BCL6
35481444	10.1080/10428194.2022.2064988	2022	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.	BCL6
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	BCL6
35489963	10.1016/j.blre.2022.100967	2022	ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.	BCL6
35495111	10.1016/j.csbj.2022.03.023	2022	Integrating whole genome sequencing, methylation, gene expression, topological associated domain information in regulatory mutation prediction: A study of follicular lymphoma.	BCL6
35503721	10.7554/eLife.69255	2022	The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress.	BCL6
35511691	10.1093/ajcp/aqac047	2022	A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.	BCL6
35521914	10.1177/10668969221099627	2022	ALK-positive Large B-Cell Lymphoma Presenting as a Circumscribed Breast Mass with Germinal Center Immunophenotype.	BCL6
35539018	10.1016/j.lrr.2022.100318	2022	A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement.	BCL6
35568724	10.1038/s41394-022-00520-y	2022	Primary intradural extramedullary spinal Burkitt's lymphoma mimicking a nerve sheath tumor: a case report.	BCL6
35583405	10.1097/DAD.0000000000002053	2022	Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma.	BCL6
35586895	10.1111/his.14674	2022	RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large-cell lymphoma.	BCL6
35600178	10.1016/j.amsu.2022.103786	2022	Immunohistochemical expression of transcription factors PAX5, OCT2, BCL6 and transcription regulator P53 in Non-Hodgkin lymphomas: A diagnostic cross-sectional study.	BCL6
35607925	10.17235/reed.2022.8765/2022	2022	Intestinal occlusion due to Burkitt lymphoma: an unusual cause.	BCL6
35640966	10.1093/humupd/dmac027	2022	BCL6, a key oncogene, in the placenta, pre-eclampsia and endometriosis.	BCL6
35646671	10.3389/fonc.2022.883141	2022	Case Report: Intravascular Large B-Cell Lymphoma: A Clinicopathologic Study of Four Cases With Review of Additional 331 Cases in the Literature.	BCL6
35652622	10.4149/neo_2022_220318N300	2022	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.	BCL6
35653645	10.1021/acs.jmedchem.1c02175	2022	Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 <i>In Vivo</i>.	BCL6
35657291	10.1021/acs.jmedchem.1c02174	2022	Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.	BCL6
35657404	10.1007/s00428-022-03342-3	2022	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.	BCL6
35664405	10.7759/cureus.24592	2022	Primary Endometrial Diffuse Large B-cell Lymphoma: A Rare Disease and Diagnostic Challenge in an Asymptomatic Postmenopausal Woman.	BCL6
35696785	10.1016/j.biomaterials.2022.121607	2022	Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma.	BCL6
35697533	10.1016/j.fertnstert.2022.05.027	2022	Reply of the Authors: B-cell lymphoma 6 (BCL6) testing before in vitro fertilization as a predictor of failure.	BCL6
35705274	10.2169/internalmedicine.9711-22	2022	Biclonal diffuse large B-cell lymphoma commonly characterized by partial trisomy 18q involving MALT1 and BCL2.	BCL6
35713502	10.1093/rheumatology/keac304	2022	TOX promotes follicular helper T cell differentiation in patients with primary Sjögren's syndrome.	BCL6
35715938	10.1002/cjp2.283	2022	Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.	BCL6
35717285	10.1016/j.fertnstert.2022.05.028	2022	B-cell lymphoma 6 (BCL6) testing before in vitro fertilization as a predictor of failure.	BCL6
35794478	10.1038/s41586-022-04906-8	2022	Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.	BCL6
35846201	10.1002/jha2.310	2022	Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report.	BCL6
35846216	10.1002/jha2.364	2022	Primary cutaneous diffuse large B-cell lymphoma, leg type with <i>MYC/BCL2/BCL6</i> overexpression.	BCL6
35869021	10.1016/j.clml.2022.06.011	2022	Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.	BCL6
35873103		2022	Neoplasms of follicular helper T-cells: an insight into the pathobiology.	BCL6
35883106	10.1186/s12935-022-02661-4	2022	DSF/Cu induces antitumor effect against diffuse large B-cell lymphoma through suppressing NF-κB/BCL6 pathways.	BCL6
35895386	10.1111/bjd.21791	2022	Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.	BCL6
35900784	10.1182/blood.2022016280	2022	EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements.	BCL6
35916066	10.1111/imcb.12578	2022	CD137L and CD4 T cells limit BCL6-expressing pre-germinal center B cell expansion and BCL6-driven B cell malignancy.	BCL6
35916333	10.1002/dc.25027	2022	HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.	BCL6
35916644	10.1097/QAI.0000000000003069	2022	Diffuse Large B-cell Lymphoma in the public-sector of Johannesburg, South Africa, in the era of widescale Anti-retroviral therapy use.	BCL6
35932211	10.1002/hon.3061	2022	Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.	BCL6
35938041	10.3389/fgene.2022.940513	2022	Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein-Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma.	BCL6
35957990	10.3389/fphys.2022.946282	2022	Molecular mechanism of hyperactive tooth root formation in oculo-facio-cardio-dental syndrome.	BCL6
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	BCL6
35982974	10.3389/fonc.2022.822805	2022	iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma.	BCL6
35997599	10.1089/vim.2021.0224	2022	Expression Pattern of Inflammatory and Anti-Inflammatory Cytokines and Key Differential Transcription Factors in Peripheral Blood Mononuclear Cells of Iranian Coronavirus Disease 2019 Patients with Different Disease Severity.	BCL6
36001789	10.46883/2022.25920970	2022	Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.	BCL6
36057749	10.1007/s00428-022-03404-6	2022	Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.	BCL6
36091937	10.3389/pore.2022.1610588	2022	Clinicopathologic Features and Treatment of CD10-Positive Mantle Cell Lymphoma: A Case Report and Review of Literature.	BCL6
32356355	10.1002/ajh.25848	2021	""Triple hit"" SOX11<sup>-</sup> , MME<sup>+</sup> , TP53 mutated high-grade pleomorphic mantle cell lymphoma.	BCL6
32590454	10.1097/PAI.0000000000000863	2021	Aberrant Cytoplasmic Terminal Deoxynucleotidyl Transferase (TdT) Immunostaining on Previously Frozen, Formalin-fixed Paraffin-embedded Tissue: Cryotomy-induced Antigen Diffusion (CIAD).	BCL6
32675470	10.1097/DAD.0000000000001737	2021	Atypical BCL6/GATA3+ Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma: A Diagnostic Challenge.	BCL6
32731312	10.1111/odi.13578	2021	Clinicopathological and genetic characteristics of diffuse large B-cell lymphoma of the oropharyngeal and maxillofacial region.	BCL6
32863365	10.2169/internalmedicine.5429-20	2021	Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass.	BCL6
32911532	10.1182/blood.2019001745	2021	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.	BCL6
32911592	10.12701/yujm.2020.00675	2021	Metachronous extranodal natural killer/T-cell lymphoma of nasal type and primary testicular lymphoma.	BCL6
32912960	10.1136/jclinpath-2020-206767	2021	<i>BCL2</i> and <i>BCL6</i> atypical/unbalanced gene rearrangements in diffuse large B-cell lymphoma are indicators of an aggressive clinical course.	BCL6
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	BCL6
32973328	10.1038/s41379-020-00685-7	2021	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.	BCL6
32979280	10.1002/hon.2811	2021	Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.	BCL6
33040061	10.1159/000509923	2021	Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.	BCL6
33058525	10.1002/dc.24642	2021	Fungating anterior chest wall mass in an adult: Cytologic diagnosis of a rare presentation.	BCL6
33120427	10.1182/blood.2020007193	2021	The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.	BCL6
33136585	10.1097/PAS.0000000000001609	2021	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.	BCL6
33150819	10.1080/08880018.2020.1838013	2021	<i>KMT2A</i>-rearranged diffuse large B-cell lymphoma in a child: a case report and molecular characterization.	BCL6
33199235	10.1016/j.intimp.2020.107137	2021	Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice.	BCL6
33252276	10.1177/1066896920977690	2021	CD10-Negative Primary Breast Follicular Lymphoma: A Rare Case of Primary Breast Lymphoma With an Atypical Immunophenotype Mimicking Marginal Zone Lymphoma.	BCL6
33258912	10.1093/ajcp/aqaa185	2021	Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay.	BCL6
33283568	10.1080/10428194.2020.1855347	2021	Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma.	BCL6
33306213	10.1002/ajh.26068	2021	First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.	BCL6
33360122	10.1016/j.cancergen.2020.12.004	2021	RNA-Based next generation sequencing complements but does not replace fluorescence in situ hybridization studies for the classification of aggressive B-Cell lymphomas.	BCL6
33392349	10.22038/AOJNMB.2020.48887.1332	2021	Incremental Value of FDG PET/CT in Aggressive High Grade B Cell lymphoma with TdT Expression.	BCL6
33393079	10.1111/his.14327	2021	Radiologically guided percutaneous core needle biopsy of the spleen: a reliable and safe diagnostic procedure for neoplastic and reactive conditions.	BCL6
33393503	10.1172/JCI133090	2021	BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.	BCL6
33398683	10.1007/s12105-020-01276-3	2021	Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma in a Geriatric Patient-Report of a Rare Case.	BCL6
33400146	10.1007/s11684-020-0821-6	2021	Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.	BCL6
33432228	10.1038/s41590-020-00827-8	2021	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.	BCL6
33468080	10.1186/s12885-021-07806-8	2021	The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma.	BCL6
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	BCL6
33480087	10.1002/hon.2839	2021	High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.	BCL6
33480830	10.1080/10428194.2020.1869965	2021	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.	BCL6
33504685	10.5045/br.2021.2020146	2021	Optimal panel of immunohistochemistry for the diagnosis of B-cell non-Hodgkin lymphoma using bone marrow biopsy: a tertiary care center study.	BCL6
33512466	10.1182/blood.2020010175	2021	OBF1 and Oct factors control the germinal center transcriptional program.	BCL6
33521119	10.12998/wjcc.v9.i2.482	2021	Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report.	BCL6
33530253	10.1097/MD.0000000000024449	2021	Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.	BCL6
33541426	10.1186/s40104-020-00541-3	2021	High expression of BCL6 inhibits the differentiation and development of hematopoietic stem cells and affects the growth and development of chickens.	BCL6
33548250	10.1016/j.humpath.2021.01.006	2021	Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.	BCL6
33551436	10.3960/jslrt.20043	2021	DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.	BCL6
33568199	10.1186/s13148-021-01007-7	2021	UHRF1 downregulation promotes T follicular helper cell differentiation by increasing BCL6 expression in SLE.	BCL6
33591648	10.1002/brb3.2061	2021	New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).	BCL6
33610538	10.1016/j.oooo.2020.11.005	2021	Oral and oropharyngeal diffuse large B-cell lymphoma and high-grade B-cell lymphoma: A clinicopathologic and prognostic study of 69 cases.	BCL6
33619998	10.1177/1066896921995942	2021	Tiny but Mighty: Collision Tumor of a Superficial Adenocarcinoma Arising From a Tubulovillous Adenoma with Associated Low-Grade Follicular Lymphoma.	BCL6
33629212	10.1007/s12032-021-01470-5	2021	Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.	BCL6
33650043	10.1007/s00428-021-03071-z	2021	Clinicopathological characterization of follicular helper T-cell-derived peripheral T-cell lymphoma involving Waldeyer's ring.	BCL6
33655392	10.1007/s00428-021-03050-4	2021	The ""Burkitt-like"" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.	BCL6
33663954	10.1016/j.it.2021.02.002	2021	Bcl6-Mediated Transcriptional Regulation of Follicular Helper T cells (T<sub>FH</sub>).	BCL6
33672644	10.3390/cancers13040887	2021	Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements.	BCL6
33683983	10.1177/1093526621999022	2021	EBV-Positive Plasmacytomas Involving a Nasopharyngeal Angiofibroma in an Adolescent.	BCL6
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	BCL6
33768318	10.1007/s00428-021-03084-8	2021	High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.	BCL6
33771538	10.1016/j.humpath.2021.03.006	2021	MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.	BCL6
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	BCL6
33786155		2021	Primary hepatic mucosa-associated lymphoid tissue lymphoma: case report and literature review.	BCL6
33786907	10.1111/cup.14020	2021	Primary cutaneous follicle center lymphoma with extensive plasmacytic differentiation and t(14;18) in both the lymphoid and plasma cell components.	BCL6
33807449	10.3390/cancers13071620	2021	High-Grade B-Cell Lymphoma (HGBL) with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan.	BCL6
33811277	10.1007/s10689-021-00244-2	2021	Constitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell lymphoma.	BCL6
33816589	10.3389/fvets.2021.647009	2021	Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma.	BCL6
33844535	10.1021/acs.jmedchem.0c01686	2021	Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.	BCL6
33858042	10.3760/cma.j.issn.0253-2727.2021.02.006	2021	[The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].	BCL6
33932086	10.1002/1878-0261.12964	2021	An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.	BCL6
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	BCL6
33965178	10.1016/j.jtct.2021.02.009	2021	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma.	BCL6
33991335	10.1111/bjh.17536	2021	In situ follicular neoplasia with translocation of BCL6 - a new variant with different immunohistochemical properties.	BCL6
34017010	10.1038/s41597-021-00915-w	2021	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set.	BCL6
34025195	10.33160/yam.2021.05.014	2021	Role of Cell-Origin Profiling Using Immunohistochemistry to Predict the Survival of Patients with Diffuse Large B-Cell Lymphoma in Indonesia.	BCL6
34049715	10.1016/j.pathol.2021.02.013	2021	Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis.	BCL6
34050029	10.1073/pnas.2104504118	2021	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma.	BCL6
34069564	10.3390/ijms22105352	2021	The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.	BCL6
34078654	10.1136/jitc-2020-002029	2021	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	BCL6
34091974	10.1111/jop.13209	2021	Burkitt lymphoma of the head and neck: An international collaborative study.	BCL6
34097157	10.1007/s11864-021-00857-w	2021	Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.	BCL6
34099699	10.1038/s41467-021-23695-8	2021	Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing.	BCL6
34105464	10.19746/j.cnki.issn.1009-2137.2021.03.012	2021	[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].	BCL6
34113336	10.3389/fimmu.2021.599493	2021	<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.	BCL6
34123811	10.3389/fonc.2021.656219	2021	Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma.	BCL6
34171161	10.1111/pin.13131	2021	Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphoma.	BCL6
34195728	10.1039/d1ob00612f	2021	Diversity-orientated synthesis of macrocyclic heterocycles using a double S<sub>N</sub>Ar approach.	BCL6
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	BCL6
34221962	10.3389/fonc.2021.638154	2021	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.	BCL6
34236648	10.1007/978-1-0716-1669-7_20	2021	Generation and Surgical Analysis of Genetic Mouse Models to Study NF-κB-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.	BCL6
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	BCL6
34274316	10.1016/j.jbc.2021.100928	2021	GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice.	BCL6
34287839	10.1002/eji.202049150	2021	BCL6 BTB-specific inhibitor reversely represses T-cell activation, Tfh cells differentiation, and germinal center reaction in vivo.	BCL6
34318932	10.1111/bjh.17734	2021	MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.	BCL6
34334687	10.1097/PAS.0000000000001726	2021	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.	BCL6
34339901	10.1016/j.clineuro.2021.106838	2021	MYC, BCL2, and BCL6 expression as prognostic indicators in primary central nervous system lymphoma: A systematic review and meta-analysis.	BCL6
34341277	10.4103/IJPM.IJPM_324_20	2021	Intravascular large B cell lymphoma of prostate, a rare entity.	BCL6
34378195	10.1111/bjh.17765	2021	Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.	BCL6
34380369	10.1080/10428194.2021.1964021	2021	Whole genome sequencing demonstrates substantial pathophysiological differences of <i>MYC</i> rearrangements in patients with plasma cell myeloma and B-cell lymphoma.	BCL6
34381423	10.3389/fendo.2021.673908	2021	Case Report: Identification of Potential Prognosis-Related <i>TP53</i> Mutation and <i>BCL6-LPP</i> Fusion in Primary Pituitary Lymphoma by Next Generation Sequencing: Two Cases.	BCL6
34384155	10.3760/cma.j.issn.0253-2727.2021.06.008	2021	[Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].	BCL6
34388250	10.1093/jnen/nlab080	2021	Expression of STAT6 and Phosphorylated STAT6 in Primary Central Nervous System Lymphomas.	BCL6
34406351	10.1093/ajcp/aqab043	2021	Light Chain-Restricted Plasmacytoid Cells in Hyperplastic Germinal CentersA Clinicopathologic Investigation.	BCL6
34426436	10.1158/1078-0432.CCR-21-0573	2021	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.	BCL6
34438040	10.1016/j.annonc.2021.08.1991	2021	SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.	BCL6
34449978	10.1002/dc.24861	2021	Angioimmunoblastic T-cell lymphoma diagnosed from pleural fluid by integration of morphologic, immunophenotypic, and molecular findings.	BCL6
34465079	10.4132/jptm.2021.07.25	2021	Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution.	BCL6
34484219	10.3389/fimmu.2021.716240	2021	Coupled Antigen and BLIMP1 Asymmetric Division With a Large Segregation Between Daughter Cells Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells and a DZ-to-LZ Ratio in the Germinal Center.	BCL6
34500469	10.1182/bloodadvances.2021004635	2021	Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.	BCL6
34528238	10.1111/bjh.17729	2021	Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.	BCL6
34558634	10.3892/mmr.2021.12458	2021	Knockdown of miR‑205‑5p alleviates the inflammatory response in allergic rhinitis by targeting B‑cell lymphoma 6.	BCL6
34588837	10.2147/BLCTT.S330008	2021	Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission.	BCL6
34596020	10.55563/clinexprheumatol/yuj21y	2021	Differential Th follicular cell subsets in minor salivary glands of patients with primary Sjögren's syndrome and systemic lupus erythematosus associated with Sjögren's syndrome.	BCL6
34610523	10.1016/j.oraloncology.2021.105552	2021	Blastoid variant of mantle cell lymphoma in palatine tonsil.	BCL6
34625792	10.1182/bloodadvances.2021005682	2021	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.	BCL6
34679437	10.3390/diagnostics11101739	2021	Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis.	BCL6
34698105	10.3390/cimb43030096	2021	Evaluation of BCL6 and SIRT1 as Non-Invasive Diagnostic Markers of Endometriosis.	BCL6
34698437	10.1111/jcmm.16999	2021	Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.	BCL6
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	BCL6
34707037	10.3960/jslrt.21025	2021	t(9;14)(p13;q32)/PAX5-IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma.	BCL6
34782660	10.1038/s41598-021-01693-6	2021	Primary central nervous system lymphomas express immunohistochemical factors of autophagy.	BCL6
34806851	10.20892/j.issn.2095-3941.2021.0193	2021	Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.	BCL6
34830747	10.3390/cancers13225592	2021	Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era.	BCL6
34877288	10.12998/wjcc.v9.i31.9542	2021	Clinical observation of pediatric-type follicular lymphomas in adult: Two case reports.	BCL6
34889402	10.1182/hematology.2021000247	2021	Double-hit lymphoma: optimizing therapy.	BCL6
34900354	10.1155/2021/6843103	2021	Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma.	BCL6
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	BCL6
34945004	10.3390/cancers13246384	2021	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.	BCL6
35004320	10.3389/fonc.2021.795330	2021	Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With <i>MYC</i> and <i>BCL6</i> Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?	BCL6
35008187	10.3390/cancers14010023	2021	Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia.	BCL6
30842630	10.1038/s41423-019-0219-z	2020	The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection.	BCL6
30968736	10.1080/07391102.2019.1606735	2020	Target prioritization of novel substituted 5-aryl-2-oxo-/thioxo-2,3-dihydro-1<i>H</i>-benzo[6,7]chromeno[2,3-<i>d</i>]pyrimidine-4,6,11(5<i>H</i>)-triones as anticancer agents using <i>in-silico</i> approach.	BCL6
31123031	10.3324/haematol.2018.214122	2020	<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.	BCL6
31197071	10.3324/haematol.2019.224121	2020	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.	BCL6
31399522	10.3324/haematol.2019.223891	2020	An increase in <i>MYC</i> copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.	BCL6
31556696	10.5858/arpa.2019-0007-OA	2020	Bone Marrow Infiltration of Angioimmunoblastic T-Cell Lymphoma: Identification and Prognostic Impact of Histologic Patterns and Diagnostic Application of Ancillary Phenotypic and Molecular Analyses.	BCL6
31571234	10.1111/jmp.12438	2020	BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta).	BCL6
31585205	10.1016/j.prro.2019.09.013	2020	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.	BCL6
31605845	10.1016/j.wneu.2019.09.158	2020	Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation.	BCL6
31615842	10.1136/jclinpath-2019-206199	2020	Clinical significance of 'double-hit' and 'double-expression' lymphomas.	BCL6
31631728	10.1080/10428194.2019.1675877	2020	The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies.	BCL6
31688139	10.1097/PAS.0000000000001390	2020	Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.	BCL6
31705772	10.1002/gcc.22825	2020	Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.	BCL6
31721454	10.1002/prca.201900091	2020	Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.	BCL6
31728727	10.1007/s00795-019-00237-2	2020	Primary mediastinal large B cell lymphoma with coexisting aberrations of C-MYC and BCL-2: a case report and literature review.	BCL6
31734190	10.1016/j.humpath.2019.09.003	2020	Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.	BCL6
31735344	10.1016/j.pathol.2019.09.008	2020	High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification.	BCL6
31743519	10.1002/jcla.23122	2020	A long non-coding RNA LNBC3 facilitates non-small cell lung cancer progression by stabilizing BCL6.	BCL6
31751845	10.1016/j.anndiagpath.2019.151421	2020	The life and death of the germinal center.	BCL6
31776129	10.1101/mcs.a004614	2020	Dramatic increase in gene mutational burden after transformation of follicular lymphoma into TdT<sup>+</sup> B-lymphoblastic leukemia/lymphoma.	BCL6
31789821	10.1097/PAI.0000000000000820	2020	EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas.	BCL6
31849147	10.1111/cas.14286	2020	Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.	BCL6
31868792	10.1097/IOP.0000000000001556	2020	Conjunctival Pediatric-Type Follicular Lymphoma.	BCL6
31870687	10.1053/j.semdp.2019.12.005	2020	Update on peripheral T-cell lymphomas with T-helper phenotype:  Are there too many subtypes?	BCL6
31872861	10.1093/ajcp/aqz172	2020	Comparison Between Integrated Genomic DNA/RNA Profiling and Fluorescence In Situ Hybridization in the Detection of MYC, BCL-2, and BCL-6 Gene Rearrangements in Large B-Cell Lymphomas.	BCL6
31882486	10.21873/invivo.11768	2020	Laryngeal Diffuse Large B-Cell Lymphoma Presenting as Laryngeal Stenosis.	BCL6
31883669	10.1016/j.pathol.2019.09.014	2020	The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.	BCL6
31892985	10.7150/jca.36954	2020	<i>C-MYC, BCL2</i> and <i>BCL6</i> Translocation in B-cell Non-Hodgkin Lymphoma Cases.	BCL6
31895575	10.1021/acs.jmedchem.9b01618	2020	Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of <i>N</i>-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth.	BCL6
31900295	10.1136/bcr-2019-231831	2020	Double-hit monomorphic B-cell lymphoma after liver transplantation.	BCL6
31903129	10.7150/thno.33482	2020	Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma.	BCL6
31903146	10.7150/thno.39018	2020	Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.	BCL6
31914056	10.1097/MD.0000000000018670	2020	Clinicopathologic features and prognostic analysis of Waldeyer ring B-cell lymphoma.	BCL6
31915197	10.1158/2159-8290.CD-19-0116	2020	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.	BCL6
31945157	10.1182/bloodadvances.2019000875	2020	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.	BCL6
31954378	10.1002/eji.201948299	2020	Bcl6 modulates innate immunity by controlling macrophage activity and plays critical role in experimental autoimmune encephalomyelitis.	BCL6
31955451	10.1002/hon.2716	2020	Diffuse large B-cell lymphoma carrying t(9;14)(p13;q32)/PAX5-immunoglobulin heavy chain gene is characterized by nuclear positivity of MUM1 and PAX5 by immunohistochemistry.	BCL6
31990228	10.5858/arpa.2019-0182-RA	2020	A Practical Approach to Diagnosis of B-Cell Lymphomas With Diffuse Large Cell Morphology.	BCL6
31991488	10.1111/apm.13029	2020	EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.	BCL6
31997133	10.1007/s12105-020-01135-1	2020	HIV-Associated ""Double-Hit"" Lymphoma of the Tonsil: A First Reported Case.	BCL6
32013324	10.4132/jptm.2019.12.17	2020	Morphologic variant of follicular lymphoma reminiscent of hyaline-vascular Castleman disease.	BCL6
32023600	10.11406/rinketsu.61.33	2020	[CD20-negative diffuse large B-cell lymphoma complicated by rheumatoid arthritis].	BCL6
32025812	10.1007/s00432-020-03137-6	2020	MYC/BCL2/BCL6 triple hit lymphoma of the pericardium: a case report and review of the literature.	BCL6
32038991	10.3389/fonc.2020.00023	2020	The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma.	BCL6
32045477	10.1182/bloodadvances.2019000359	2020	Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.	BCL6
32061875	10.1016/j.jim.2020.112753	2020	T follicular helper and T follicular regulatory cells in colorectal cancer: A complex interplay.	BCL6
32062068	10.1016/j.neo.2020.01.002	2020	AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.	BCL6
32066288	10.1080/14656566.2020.1727445	2020	Perspectives on chemotherapy for the management of double-hit lymphoma.	BCL6
32074595	10.1159/000505892	2020	The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.	BCL6
32100426	10.1111/1756-185X.13800	2020	Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren's syndrome.	BCL6
32112707	10.1093/ajcp/aqz208	2020	Double-Hit and Triple-Hit Follicular Lymphoma.	BCL6
32130407	10.1182/bloodadvances.2019001114	2020	Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk.	BCL6
32131762	10.1186/s12885-020-6650-9	2020	Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.	BCL6
32139607	10.1073/pnas.1920419117	2020	Distinct signaling and transcriptional pathways regulate peri-weaning development and cold-induced recruitment of beige adipocytes.	BCL6
32144513	10.1007/s11912-020-0898-8	2020	Burkitt and Burkitt-Like Lymphomas: a Systematic Review.	BCL6
32152442	10.1038/s41598-020-61378-4	2020	A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era.	BCL6
32180900	10.18632/oncotarget.27506	2020	Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis.	BCL6
32195944	10.1097/MD.0000000000019463	2020	Primary testicular diffuse large B-cell lymphoma: Case series.	BCL6
32210715	10.7150/ijms.41075	2020	Connective tissue growth factor (CTGF) regulates the fusion of osteoclast precursors by inhibiting Bcl6 in periodontitis.	BCL6
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	BCL6
32240660	10.1016/j.yexcr.2020.111986	2020	Establishment and characterization of a porcine B cell lymphoma cell line.	BCL6
32245492	10.1186/s13000-020-00932-0	2020	A rare face of follicular lymphoma: reverse variant of follicular lymphoma.	BCL6
32260556	10.3390/cancers12040884	2020	Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.	BCL6
32275432	10.1021/acs.jmedchem.9b02076	2020	Achieving <i>In Vivo</i> Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders.	BCL6
32277518	10.1002/jcb.29650	2020	Hsa_circ_0031288/hsa-miR-139-3p/Bcl-6 regulatory feedback circuit influences the invasion and migration of cervical cancer HeLa cells.	BCL6
32281588		2020	Classifying DLBCL according cell of origin using Hans algorithm and its association with clinicopathological parameters: A single centre experience.	BCL6
32287077	10.1097/PAI.0000000000000843	2020	Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.	BCL6
32311849	10.3343/alm.2020.40.5.361	2020	Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.	BCL6
32320427	10.1371/journal.pone.0231470	2020	The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy.	BCL6
32334477	10.31557/APJCP.2020.21.4.1103	2020	The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.	BCL6
32363958	10.1177/0300060520918087	2020	CD56-positive diffuse large B-cell lymphoma/leukemia with <i>BCL6/MYC</i> double-hit and multiple gene mutations: an indicator of poor prognosis?	BCL6
32364682	10.1111/ijlh.13222	2020	Significance of CD10 protein expression in the diagnostics of follicular lymphoma: A comparison of conventional immunohistochemistry with flow cytometry supported by the establishment of BCL2 and BCL6 rearrangements.	BCL6
32424816	10.1111/jgh.15083	2020	Gastrointestinal: Inflammatory bowel disease therapy-induced triple-hit lymphoma.	BCL6
32491282	10.1002/dc.24477	2020	Anaplastic large cell lymphoma: Report of two cases with rare patterns (carcinomatous and sarcomatous) in fine needle aspiration cytology and histopathology.	BCL6
32497402	10.1002/cyto.b.21887	2020	Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.	BCL6
32507816	10.11406/rinketsu.61.503	2020	[Genetic alterations and lymphoma].	BCL6
32535543	10.1016/j.cancergen.2020.05.002	2020	Generation and characterization of the Eµ-Irf8 mouse model.	BCL6
32541138	10.1159/000505715	2020	Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions.	BCL6
32546802	10.1038/s41598-020-66539-z	2020	Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice.	BCL6
32551010	10.1021/acsmedchemlett.0c00111	2020	Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.	BCL6
32613279	10.1007/s00277-020-04124-0	2020	Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.	BCL6
32619424	10.1016/j.cell.2020.05.049	2020	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.	BCL6
32639587	10.1002/hon.2779	2020	Primary large B-cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma with CCND1 rearrangement or mantle cell lymphoma?	BCL6
32648273	10.1111/pin.12981	2020	RHOA mutation in follicular T-cell lymphoma: Clinicopathological analysis of 16 cases.	BCL6
32679859	10.3390/cancers12071912	2020	Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type.	BCL6
32680911	10.1136/jclinpath-2020-206725	2020	Incidence of single hit Bcl-2 and Bcl-6 rearrangements in DLBCL: the Irish experience.	BCL6
32713346	10.1186/s13256-020-02433-6	2020	Transformation of a low-grade follicular lymphoma into a composite lymphoma combining a high-grade B-cell lymphoma and a lymphoblastic neoplasm expressing Terminal deoxynucleotidyl Transferase: a case report.	BCL6
32722781	10.1182/bloodadvances.2020001551	2020	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.	BCL6
32736575	10.1186/s12885-020-07198-1	2020	Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.	BCL6
32780847	10.1182/bloodadvances.2020001727	2020	Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.	BCL6
32780869	10.1111/bjh.17038	2020	Indolent clinical behaviour of primary cutaneous diffuse large B-cell lymphoma, leg type, with double MYC and BCL6 gene rearrangement.	BCL6
32843454	10.1136/bcr-2020-235451	2020	High-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a cervical mass.	BCL6
32843697	10.1038/s41598-020-71058-y	2020	Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy.	BCL6
32851455	10.1007/s00277-020-04218-9	2020	A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation.	BCL6
32888407	10.1016/S0140-6736(20)31366-0	2020	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.	BCL6
32889391	10.1016/j.anndiagpath.2020.151610	2020	Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.	BCL6
32909092	10.1007/s00292-020-00816-6	2020	[Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].	BCL6
32921221	10.1080/10428194.2020.1815017	2020	Clinicopathological and prognostic significance of <i>BCL2</i>, <i>BCL6</i>, <i>MYC</i>, and <i>IRF4</i> copy number gains and translocations in follicular lymphoma: a study by FISH analysis.	BCL6
32947237	10.1016/j.tranon.2020.100855	2020	Identification of clinical molecular targets for childhood Burkitt lymphoma.	BCL6
32991338	10.1097/PAS.0000000000001577	2020	High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.	BCL6
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	BCL6
33048405	10.1111/pin.13031	2020	The first reported case of primary extranodal counterpart of follicular T-cell lymphoma of submandibular gland.	BCL6
33065767	10.1111/bjh.17072	2020	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.	BCL6
33066681	10.3390/diagnostics10100823	2020	Use of Liquid-based Cytology and Cell Block Combined Technique for an Accurate Diagnosis of Oral Diffuse Large B Cell Lymphoma: A Case Report.	BCL6
33082762	10.1159/000510362	2020	Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders, Diffuse Large B-Cell Lymphoma Type, in a Patient with Behçet's Disease Treated with Cyclosporine A.	BCL6
33094287	10.1093/narcan/zcaa029	2020	Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma.	BCL6
33100703	10.1007/s12288-019-01248-w	2020	Double Hit and Double Expresser Diffuse Large B Cell Lymphoma Subtypes: Discrete Subtypes and Major Predictors of Overall Survival.	BCL6
33168821	10.1038/s41408-020-00382-3	2020	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.	BCL6
33176509	10.1080/17474086.2020.1850252	2020	An analysis of genetic targets for guiding clinical management of follicular lymphoma.	BCL6
33180881	10.1371/journal.pone.0241634	2020	Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?	BCL6
33182312	10.3390/ijms21218393	2020	The Function of Oncogene B-Cell Lymphoma 6 in the Regulation of the Migration and Invasion of Trophoblastic Cells.	BCL6
33208943	10.1038/s41586-020-2925-1	2020	Small-molecule-induced polymerization triggers degradation of BCL6.	BCL6
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	BCL6
33232656	10.1016/j.molcel.2020.10.036	2020	Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage.	BCL6
33275671	10.1182/hematology.2020000115	2020	Transformed lymphoma: what should I do now?	BCL6
33288562	10.21873/anticanres.14692	2020	EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.	BCL6
33293491		2020	FISH is Still an Excellent Tool to Monitor High-Grade Lymphomas.	BCL6
33304974	10.1016/j.jdcr.2020.08.041	2020	Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment.	BCL6
33318279	10.1136/bcr-2020-238626	2020	Primary intestinal follicular lymphoma presenting as multiple lymphomatous polyposis.	BCL6
33333642	10.3760/cma.j.cn112147-20200729-00859	2020	[Pulmonary mucosa-associated lymphoid tissue lymphoma concurrent with lung squamous cell carcinoma: a case report and literature review].	BCL6
33365186	10.25259/SNI_314_2020	2020	Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.	BCL6
33376737	10.1155/2020/7467104	2020	Pyruvate Kinase M2 Knockdown Suppresses Migration, Invasion, and Epithelial-Mesenchymal Transition of Gastric Carcinoma via Hypoxia-Inducible Factor Alpha/B-Cell Lymphoma 6 Pathway.	BCL6
33425899	10.3389/fcell.2020.594785	2020	CircHmbox1 Targeting miRNA-1247-5p Is Involved in the Regulation of Bone Metabolism by TNF-α in Postmenopausal Osteoporosis.	BCL6
33437697	10.4103/ajm.ajm_81_20	2020	High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma.	BCL6
33463110	10.18502/ijaai.v19i4.4118	2020	Increased Expression of B Lymphocyte Induced Maturation Protein 1 (BLIMP1) in Patients with Common Variable Immunodeficiency (CVID).	BCL6
33550334		2020	[Clinicopathological analysis of mucosa associated lymphoid tissue lymphoma secondary to Sjögren' s syndrome in salivary gland].	BCL6
33613551	10.3389/fimmu.2020.620716	2020	Multiscale Modeling of Germinal Center Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells Differentiation as Regulated by Antigen Affinity-Based Tfh Cell Help.	BCL6
33633728	10.3389/fimmu.2020.607626	2020	<i>In Situ</i> Characterization of Follicular Helper CD4 T Cells Using Multiplexed Imaging.	BCL6
34595452	10.2991/chi.d.200410.001	2020	Cost Analysis of R-CHOP <i>Versus</i> Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features.	BCL6
35847735	10.1002/jha2.28	2020	Relapse of follicular lymphoma arising from a non-t(14;18) clone.	BCL6
30105896	10.1002/jcp.27045	2019	Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).	BCL6
30179888	10.1097/PAI.0000000000000696	2019	nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin.	BCL6
30181564	10.1038/s41379-018-0112-9	2019	High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma.	BCL6
30210134	10.2169/internalmedicine.1686-18	2019	Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.	BCL6
30277098	10.1080/10428194.2018.1508663	2019	Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.	BCL6
30277117	10.1080/10428194.2018.1516286	2019	Cytotoxic effect caspase activation dependent of a genetically engineered fusion protein with a CD154 peptide mimetic (OmpC-CD154<sub>p</sub>) on B-NHL cell lines is mediated by the inhibition of bcl-6 and YY1 through MAPK p38 activation.	BCL6
30279226	10.1182/blood-2018-03-839993	2019	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.	BCL6
30306208	10.1007/s00277-018-3498-z	2019	MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.	BCL6
30309852	10.3324/haematol.2018.198572	2019	Targeted next generation sequencing reveals high mutation frequency of <i>CREBBP, BCL2</i> and <i>KMT2D</i> in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements.	BCL6
30348636	10.1158/1078-0432.CCR-18-1153	2019	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.	BCL6
30355686	10.1128/JVI.01073-18	2019	BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.	BCL6
30380402	10.1016/j.anndiagpath.2018.09.014	2019	Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.	BCL6
30409904	10.1074/jbc.RA118.004204	2019	Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression.	BCL6
30446717	10.1038/s41374-018-0152-2	2019	MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.	BCL6
30457458	10.1080/10428194.2018.1506586	2019	Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations.	BCL6
30460680	10.1111/bjh.15653	2019	Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	BCL6
30496802	10.1016/j.humpath.2018.11.015	2019	p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.	BCL6
30523716	10.1200/JCO.18.01583	2019	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.	BCL6
30523719	10.1200/JCO.18.01314	2019	Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.	BCL6
30538335	10.1038/s41590-018-0273-1	2019	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis.	BCL6
30567732	10.4049/jimmunol.1800876	2019	BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.	BCL6
30573511	10.3324/haematol.2018.195834	2019	Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.	BCL6
30608910	10.1097/DAD.0000000000001076	2019	Cutaneous Involvement in a High Grade B-Cell Lymphoma With Rearrangement of MYC, BCL2, and BCL6 Transformed From Follicular Lymphoma.	BCL6
30613837	10.1007/s00277-018-03590-x	2019	Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma.	BCL6
30636538	10.1177/0300985818823775	2019	Primary Colorectal Follicular Lymphoma in 3 Dogs.	BCL6
30653103	10.1097/MD.0000000000013985	2019	Colorectal follicular lymphoma: A case report.	BCL6
30680935	10.1002/jez.b.22843	2019	Bcl6aa and bcl6ab are ubiquitously expressed and are inducible by lipopolysaccharide and polyI:C in adult tissues of medaka Oryzias latipes.	BCL6
30719149	10.7150/jca.25732	2019	BCL6 Rearrangement Indicates Poor Prognosis in Diffuse Large B-cell Lymphoma Patients: A Meta-analysis of Cohort Studies.	BCL6
30732171	10.1097/MD.0000000000014367	2019	Diffuse large B-cell lymphoma of the central nervous system presenting as ""lymphomatosis cerebri"" and dementia in elderly man: Case report and review of the literature.	BCL6
30734478	10.1002/cyto.b.21770	2019	Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.	BCL6
30737994	10.1111/ejh.13219	2019	Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-Identifies a subgroup of patients with poor outcome.	BCL6
30768141	10.1093/asj/sjz044	2019	The First Reported Case of Gluteal Implant-Associated Anaplastic Large Cell Lymphoma (ALCL).	BCL6
30788082	10.1016/j.csbj.2019.01.006	2019	Bivalent Ligands for Protein Degradation in Drug Discovery.	BCL6
30792929	10.1155/2019/3730915	2019	CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.	BCL6
30805081	10.1155/2019/5018410	2019	BCL6 Attenuates Proliferation and Oxidative Stress of Vascular Smooth Muscle Cells in Hypertension.	BCL6
30809101	10.2147/CMAR.S192143	2019	Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with <i>MYC</i>, <i>BCL2/BCL6</i> gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study.	BCL6
30824609	10.1158/1535-7163.MCT-18-1068	2019	HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.	BCL6
30839349	10.1097/DAD.0000000000001368	2019	AL-Amyloidoma of the Skin-A Rare Manifestation of Primary Cutaneous Marginal Zone Lymphoma.	BCL6
30859597	10.1002/ajh.25460	2019	Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.	BCL6
30874346	10.1111/imr.12734	2019	MYC in Germinal Center-derived lymphomas: Mechanisms and therapeutic opportunities.	BCL6
30874354	10.1111/imr.12755	2019	Germinal center-derived lymphomas: The darkest side of humoral immunity.	BCL6
30917792	10.1186/s12885-019-5466-y	2019	The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.	BCL6
30918199	10.2169/internalmedicine.2532-18	2019	Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t (3;7) (q27;p12) and t (8;14) (q24;q32) Translocations.	BCL6
30952970	10.1038/s41379-019-0254-4	2019	The pathological features of angioimmunoblastic T-cell lymphomas with IDH2<sup>R172</sup> mutations.	BCL6
30963474	10.1007/s12185-019-02646-6	2019	Double-hit pancreatic B-lymphoblastic lymphoma with a variant translocation t(2;18)(p11;q21).	BCL6
30980412	10.1111/cup.13475	2019	Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features.	BCL6
30983044	10.1111/cyt.12707	2019	The accuracy of diagnosing Burkitt lymphoma in serous effusion specimen: A cytological-histological correlation with ancillary studies.	BCL6
30983568	10.7554/eLife.43922	2019	Dynamic repression by BCL6 controls the genome-wide liver response to fasting and steatosis.	BCL6
30992267	10.1182/blood.2018864173	2019	Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background.	BCL6
31000603	10.1073/pnas.1901258116	2019	Transcription factors IRF8 and PU.1 are required for follicular B cell development and BCL6-driven germinal center responses.	BCL6
31024321	10.3389/fphar.2019.00367	2019	Inhibitory Effect of KP-A038 on Osteoclastogenesis and Inflammatory Bone Loss Is Associated With Downregulation of Blimp1.	BCL6
31025641		2019	Diffuse large B-cell lymphoma of the small intestine in a patient with refractory coeliac disease.	BCL6
31030723		2019	[T follicular helper cells and their related molecules in rheumatoid arthritis: A review].	BCL6
31042473	10.1016/j.celrep.2019.04.014	2019	Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.	BCL6
31045473	10.1200/JGO.18.00203	2019	Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin.	BCL6
31063496	10.1371/journal.pone.0216470	2019	Generation and characterization of a monoclonal antibody against human BCL6 for immunohistochemical diagnosis.	BCL6
31068510	10.11406/rinketsu.60.155	2019	[MYC-associated B-cell lymphomas: pathophysiology and treatment].	BCL6
31072235	10.1080/16078454.2019.1614289	2019	Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.	BCL6
31095175	10.4067/s0034-98872019000200247	2019	[Triple expressor lymphoma in a kidney transplant patient].	BCL6
31109360	10.1186/s13000-019-0826-0	2019	Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.	BCL6
31150587	10.1080/17474086.2019.1624157	2019	High-grade B-cell lymphoma: how to diagnose and treat.	BCL6
31155767	10.1111/jpn.13110	2019	Dietary l-arginine supplementation influences growth performance and B-cell secretion of immunoglobulin in broiler chickens.	BCL6
31160360	10.1101/mcs.a004077	2019	Elucidating a false-negative <i>MYC</i> break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with <i>IGH/MYC</i> and <i>IGH/BCL2</i> rearrangements.	BCL6
31171907	10.7150/ijms.27610	2019	Clinical Significance of <i>BCL2</i>, C-<i>MYC</i>, and <i>BCL6</i> Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.	BCL6
31185999	10.1186/s12967-019-1951-y	2019	Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL.	BCL6
31187528	10.1002/hon.2581	2019	Double-hit lymphoma: So what?	BCL6
31189479	10.1186/s13000-019-0833-1	2019	Treatment outcome and prognostic factors in PCNSL.	BCL6
31205728	10.1136/lupus-2019-000324	2019	Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival.	BCL6
31225766	10.1080/10428194.2019.1622099	2019	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status.	BCL6
31229156	10.1016/j.hoc.2019.04.001	2019	Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements.	BCL6
31281146	10.11406/rinketsu.60.570	2019	[BCL2, BCL6, and MYC-positive intravascular large B-cell lymphoma presenting with bilateral adrenal gland lesions].	BCL6
31283630	10.1097/PAS.0000000000001315	2019	Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype.	BCL6
31285189	10.1182/bloodadvances.2019000251	2019	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.	BCL6
31285322	10.1073/pnas.1905305116	2019	Nbn-Mre11 interaction is required for tumor suppression and genomic integrity.	BCL6
31287161	10.1002/cncr.32145	2019	Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?	BCL6
31288832	10.1186/s13045-019-0761-2	2019	Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.	BCL6
31315646	10.1186/s13000-019-0856-7	2019	Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.	BCL6
31336593	10.3390/jcm8071074	2019	Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.	BCL6
31365872	10.1016/j.celrep.2019.06.079	2019	CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation.	BCL6
31368914	10.1097/PAS.0000000000001338	2019	Indolent In Situ B-Cell Neoplasms With MYC Rearrangements Show Somatic Mutations in MYC and TNFRSF14 by Next-generation Sequencing.	BCL6
31375635	10.1073/pnas.1907308116	2019	BCL6 regulates brown adipocyte dormancy to maintain thermogenic reserve and fitness.	BCL6
31395741	10.1101/gad.327593.119	2019	Rationale for targeting BCL6 in <i>MLL</i>-rearranged acute lymphoblastic leukemia.	BCL6
31401377	10.1016/j.intimp.2019.105789	2019	BCL6 inhibitor FX1 attenuates inflammatory responses in murine sepsis through strengthening BCL6 binding affinity to downstream target gene promoters.	BCL6
31404445	10.1007/s12308-019-00354-y	2019	Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.	BCL6
31406071	10.11405/nisshoshi.116.660	2019	[Mucosa-associated lymphoid tissue lymphoma of the appendix concomitant with appendicitis:a case report].	BCL6
31408531	10.1002/hon.2664	2019	PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.	BCL6
31416638	10.1016/j.annpat.2019.05.005	2019	[New entities and new tools in hematopathology as proposed by the 2016 WHO classification: Case 2].	BCL6
31419226	10.1371/journal.pone.0220681	2019	DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.	BCL6
31427546		2019	Characterisation of immunogenotypes of diffuse large B-cell lymphoma.	BCL6
31440479	10.4322/acr.2019.090	2019	High-grade B-Cell lymphoma with <i>MYC</i> and <i>BCL6</i> rearrangements associated with Richter transformation of chronic lymphocytic leukemia.	BCL6
31498031	10.1200/JCO.19.00743	2019	Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.	BCL6
31518494	10.17219/acem/109200	2019	A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification.	BCL6
31527075	10.1182/blood.2019002600	2019	The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.	BCL6
31558468	10.1182/blood.2019001880	2019	The whole-genome landscape of Burkitt lymphoma subtypes.	BCL6
31565620	10.7759/cureus.5217	2019	CD-20 Negative Plasmablastic Lymphoma Lurking in the Shadow of a Leiomyoma - Diagnosis and Management.	BCL6
31584842	10.5858/arpa.2019-0331-RA	2019	Ancillary Studies in the Diagnostic Evaluation of Large B-Cell Lymphoma.	BCL6
31586036	10.4049/jimmunol.1900326	2019	<i>Crlz-1</i> Controls Germinal Center Reaction by Relaying a Wnt Signal to the <i>Bcl-6</i> Expression in Centroblasts during Humoral Immune Responses.	BCL6
31586074	10.1038/s41467-019-12494-x	2019	Genetic modification of primary human B cells to model high-grade lymphoma.	BCL6
31611445	10.4103/IJPM.IJPM_849_18	2019	Primary epiglottic follicular variant of peripheral T-cell lymphoma.	BCL6
31666176	10.1016/j.pathol.2019.08.009	2019	TdT-positive high grade B-cell lymphoma transformed from grade 3B follicular lymphoma in an HIV-positive patient.	BCL6
31686194	10.1007/s00428-019-02681-y	2019	Novel markers in pediatric-type follicular lymphoma.	BCL6
31692510	10.2147/BLCTT.S216292	2019	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens.	BCL6
31711493	10.1186/s12903-019-0936-9	2019	Follicular lymphoid hyperplasia of the posterior maxillary site presenting as uncommon entity: a case report and review of the literature.	BCL6
31712669	10.1038/s41598-019-52714-4	2019	Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.	BCL6
31748270	10.1073/pnas.1914163116	2019	A high-resolution landscape of mutations in the <i>BCL6</i> super-enhancer in normal human B cells.	BCL6
31752970	10.1186/s13045-019-0803-9	2019	Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.	BCL6
31788471	10.3389/fcell.2019.00272	2019	Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation.	BCL6
31805190	10.1182/bloodadvances.2019000989	2019	Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray.	BCL6
31844420	10.7573/dic.2019-8-1	2019	Drug therapy for double-hit lymphoma.	BCL6
31934044		2019	The impact of <i>BCL-2/MYC</i> protein expression and gene abnormality on primary central nervous system diffuse large B-cell lymphoma.	BCL6
31942539	10.1097/HS9.0000000000000284	2019	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?	BCL6
31993568	10.1016/j.mayocpiqo.2019.08.004	2019	Quality Initiative in Clinical Practice: A Single-Institution Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma.	BCL6
32397023	10.3760/cma.j.issn.0253-2727.2019.07.010	2019	[Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].	BCL6
32598736	10.26442/00403660.2019.07.000070	2019	[The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].	BCL6
34468358	10.1158/2159-8290.CD-RW2018-216	2019	BCL6-Driven Lymphoma Is Dependent on LSD1 Corepression.	BCL6
28875547	10.1111/bjh.14912	2018	Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma.	BCL6
29352142	10.1038/s41419-017-0066-8	2018	FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.	BCL6
29510136	10.1016/j.bbrc.2018.03.010	2018	Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells.	BCL6
29510377	10.1159/000487372	2018	miR-519d-3p Inhibits Cell Proliferation and Invasion of Gastric Cancer by Downregulating B-Cell Lymphoma 6.	BCL6
29983382	10.1016/j.clml.2018.06.010	2018	Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.	BCL6
30043475	10.1002/dc.24038	2018	""Triple hit"" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.	BCL6
30082494	10.1182/blood-2018-02-831438	2018	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.	BCL6
30089946	10.4103/JOC.JOC_42_18	2018	Contribution of Immunocytochemistry to the Diagnosis of Usual and Unusual Lymphoma Cases.	BCL6
30103201	10.1016/j.leukres.2018.08.002	2018	Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia.	BCL6
30109672	10.1007/s11060-018-2970-x	2018	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.	BCL6
30111411	10.7534/j.issn.1009-2137.2018.04.023	2018	[Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].	BCL6
30113335	10.1097/PAS.0000000000001132	2018	High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.	BCL6
30143009	10.1186/s12964-018-0258-6	2018	Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.	BCL6
30146835	10.7754/Clin.Lab.2018.180320	2018	Diffuse Large B Cell Lymphoma Coexistent with Follicular Cell Lymphoma.	BCL6
30158513	10.12659/AJCR.909400	2018	Double-Hit Lymphoma (MYC and BCL6) with Involvement of Skull and Adnexal Lesions: A Case Report and a Review of the Literature.	BCL6
30171453	10.1007/s11060-018-2990-6	2018	Characterization of genomic alterations in primary central nervous system lymphomas.	BCL6
30185437	10.1182/bloodadvances.2018021063	2018	STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.	BCL6
30195499	10.1016/j.acthis.2018.08.003	2018	Silymarin amplifies apoptosis in ectopic endometrial tissue in rats with endometriosis; implication on growth factor GDNF, ERK1/2 and Bcl-6b expression.	BCL6
30213388	10.1016/j.beha.2018.07.003	2018	Dissecting aggressive B-cell lymphoma through genomic analysis - What is clinically relevant?	BCL6
30213392	10.1016/j.beha.2018.07.012	2018	Double hit lymphoma: How do we define it and how do we treat it?	BCL6
30213394	10.1016/j.beha.2018.07.008	2018	An update in treating transformed lymphoma.	BCL6
30235749	10.1097/MD.0000000000012482	2018	Adrenal relapse of primary central nervous system diffuse large B-cell lymphoma: A case report.	BCL6
30245984		2018	Mantle Cell Lymphoma of the Palatine Tonsil: A Rare Case Report.	BCL6
30252929	10.1002/cncr.31646	2018	Double hit and double expressors in lymphoma: Definition and treatment.	BCL6
30255584	10.1111/pin.12722	2018	Synchronous case of follicular lymphoma and Langerhans cell sarcoma in the same lymph node.	BCL6
30279867	10.1016/j.jccase.2017.11.002	2018	Primary cardiac MYC/BCL6 double hit non-Hodgkin lymphoma.	BCL6
30287880	10.1038/s41598-018-33230-3	2018	Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.	BCL6
30305516	10.11406/rinketsu.59.2109	2018	[Treatment strategy for high-grade B-cell lymphoma].	BCL6
30323893	10.18632/oncotarget.26060	2018	Generation and characteristics of a novel ""double-hit"" high grade B-cell lymphoma cell line DH-My6 with <i>MYC</i>/<i>IGH</i> and <i>BCL6</i>/<i>IGH</i> gene arrangements and potential molecular targeted therapies.	BCL6
30333862	10.3892/ol.2018.9376	2018	miR-339-5p inhibits lung adenocarcinoma invasion and migration by directly targeting BCL6.	BCL6
30335946	10.1021/acschembio.8b00698	2018	Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.	BCL6
30348671	10.1182/bloodadvances.2018023572	2018	High-resolution architecture and partner genes of <i>MYC</i> rearrangements in lymphoma with DLBCL morphology.	BCL6
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	BCL6
30395539	10.1172/JCI124919	2018	PLK1: a promising and previously unexplored target in double-hit lymphoma.	BCL6
30498195	10.1038/s41467-018-06961-0	2018	Chromatin conformation analysis of primary patient tissue using a low input Hi-C method.	BCL6
30501868	10.1016/S2352-3026(18)30177-7	2018	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.	BCL6
30504293	10.1182/asheducation-2018.1.69	2018	Genomics of aggressive B-cell lymphoma.	BCL6
30521492		2018	Two Double-hit Lymphomas Cases: A Molecular Cytogenetic Approach.	BCL6
30553470	10.1016/j.cancergen.2018.08.001	2018	Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.	BCL6
30564339	10.1002/ccr3.1871	2018	A double-hit High-grade B-cell lymphoma with three-way translocation t(3;8;14)(q27;q24;q32) involving BCL6, MYC, and IGH.	BCL6
30566857	10.1016/j.celrep.2018.11.074	2018	Loss of Transcriptional Repression by BCL6 Confers Insulin Sensitivity in the Setting of Obesity.	BCL6
30586419	10.1371/journal.pone.0210027	2018	Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.	BCL6
30687256	10.3389/fmicb.2018.03253	2018	B-Cell Lymphoma 6 (BCL6) Is a Host Restriction Factor That Can Suppress HBV Gene Expression and Modulate Immune Responses.	BCL6
30949014	10.1080/08998280.2018.1460127	2018	RETRACTED ARTICLE: Primary central nervous system high-grade B-cell lymphoma, with rearrangements of <i>MYC</i> and <i>BCL6</i>.	BCL6
31007628	10.1080/08998280.2019.1578105	2018	RETRACTED ARTICLE: Primary central nervous system high-grade B-cell lymphoma, with rearrangements of <i>MYC</i> and <i>BCL6</i>.	BCL6
27921272	10.1007/s12185-016-2159-z	2017	BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma.	BCL6
28030830	10.18632/oncotarget.14038	2017	Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia.	BCL6
28256570	10.1038/modpathol.2017.12	2017	Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma.	BCL6
28628241	10.1111/his.13286	2017	Aberrant expression of CD10 and BCL6 in mantle cell lymphoma.	BCL6
28665415	10.1038/bcj.2017.59	2017	Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas.	BCL6
28952038	10.1007/s11912-017-0629-y	2017	Double-Hit Large B Cell Lymphoma.	BCL6
29056123	2721	2017	Immunohistochemical Expression of CD10, BCL6 and MUM1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes.	BCL6
29072703	10.1038/cddis.2017.567	2017	BCL6 attenuates renal inflammation via negative regulation of NLRP3 transcription.	BCL6
29088292	10.1371/journal.pone.0186983	2017	Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.	BCL6
30802397	10.18821/0869-2084-2017-62-8-490-497	2017	[The complex morphologic diagnostic of marginal zone lymphoma.]	BCL6
26120879	10.1080/09168451.2015.1056512	2016	Development and function of follicular helper T cells.	BCL6
26414904	10.1002/cncy.21626	2016	CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.	BCL6
26448193	10.1097/PAS.0000000000000542	2016	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.	BCL6
26553360	10.1007/s13277-015-4390-2	2016	miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.	BCL6
26565895	10.1002/cncr.29781	2016	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.	BCL6
26573234	10.18632/oncotarget.6262	2016	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.	BCL6
26710884	10.1038/leu.2015.355	2016	SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6.	BCL6
26728228	10.1038/srep18778	2016	Bcl6 Sets a Threshold for Antiviral Signaling by Restraining IRF7 Transcriptional Program.	BCL6
26986233	10.3892/ijmm.2016.2529	2016	Overexpression of miR-155 promotes the proliferation and invasion of oral squamous carcinoma cells by regulating BCL6/cyclin D2.	BCL6
27069113	10.1084/jem.20151724	2016	B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6.	BCL6
27268052	10.1074/jbc.M116.736868	2016	Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.	BCL6
27363279		2016	[Increased expressions of Blimp-1 and Bcl-6 in the deciduas of patients with unexplained recurrent spontaneous abortion].	BCL6
27494852	10.18632/oncotarget.10993	2016	PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.	BCL6
27764808	10.18632/oncotarget.12680	2016	The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma.	BCL6
27815824	10.1007/s13238-016-0316-z	2016	miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.	BCL6
24362533	10.1038/onc.2013.535	2015	Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.	BCL6
24679006	10.3109/10428194.2014.907896	2015	TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.	BCL6
25543051	10.1093/toxsci/kfu257	2015	Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6.	BCL6
25557390	10.1016/j.bbadis.2014.12.018	2015	The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases.	BCL6
25596256	10.1309/AJCPUIDW2CPTA1JA	2015	Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases.	BCL6
25769544	10.3324/haematol.2014.120048	2015	BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.	BCL6
25828391	10.1097/PAS.0000000000000434	2015	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.	BCL6
26049022	10.1016/j.canlet.2015.05.029	2015	BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells.	BCL6
26054109		2015	Decreased Bcl-6 and increased Blimp-1 in the peritoneal cavity of patients with endometriosis.	BCL6
26214636		2015	BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.	BCL6
26276666	10.1182/blood-2015-07-657999	2015	Convergent BCL6 and lncRNA promoters demarcate the major breakpoint region for BCL6 translocations.	BCL6
24114011	10.1007/s13277-013-1195-z	2014	BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma.	BCL6
24678684	10.5858/arpa.2012-0663-OA	2014	Fluorescence immunophenotyping and interphase cytogenetics (FICTION) detects BCL6 abnormalities, including gene amplification, in most cases of nodular lymphocyte-predominant Hodgkin lymphoma.	BCL6
24698494	10.1016/j.molmed.2014.03.001	2014	Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis.	BCL6
24767250	10.1016/j.humpath.2014.02.002	2014	Targeted gene analysis: increased B-cell lymphoma 6 in preeclamptic placentas.	BCL6
24863065	10.1084/jem.20132267	2014	A negative feedback loop mediated by the Bcl6-cullin 3 complex limits Tfh cell differentiation.	BCL6
24878528	10.1016/j.bbrc.2014.05.096	2014	High concentrations of glucose suppress etoposide-induced cell death of B-cell lymphoma through BCL-6.	BCL6
24887457	10.1038/ncomms4904	2014	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.	BCL6
24917186	10.1186/1471-2407-14-418	2014	B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells.	BCL6
25038272	10.1016/j.canlet.2014.06.017	2014	Translocation of the proto-oncogene Bcl-6 in human glioblastoma multiforme.	BCL6
25090026	10.1371/journal.pone.0104068	2014	MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.	BCL6
25125624	10.1309/AJCPBWVHTF7RRSA4	2014	Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.	BCL6
25234312	10.1152/ajprenal.00426.2014	2014	Transcriptional regulation of human organic anion transporter 1 by B-cell CLL/lymphoma 6.	BCL6
25245533	10.18632/oncotarget.2364	2014	Interleukin-32α downregulates the activity of the B-cell CLL/lymphoma 6 protein by inhibiting protein kinase Cε-dependent SUMO-2 modification.	BCL6
25295537	10.1172/JCI75667	2014	Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination.	BCL6
25297597	10.3760/cma.j.issn.1003-9406.2014.01.020	2014	[Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].	BCL6
25490446	10.1016/j.ccell.2014.10.021	2014	A BCL6/BCOR/SIRT1 complex triggers neurogenesis and suppresses medulloblastoma by repressing Sonic Hedgehog signaling.	BCL6
22893614	10.1002/jbmr.1739	2013	Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling.	BCL6
23269799	10.1128/JVI.03081-12	2013	B cells in chronically hepatitis C virus-infected individuals lack a virus-induced mutation signature in the TP53, CTNNB1, and BCL6 genes.	BCL6
23335369	10.1182/blood-2012-06-435842	2013	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.	BCL6
23348205	10.1097/PAS.0b013e31826cebad	2013	Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.	BCL6
23476051	10.1182/blood-2012-10-464958	2013	BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements.	BCL6
23509938	10.1111/his.12076	2013	Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups.	BCL6
23716595	10.1128/MCB.01620-12	2013	STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.	BCL6
23749188	10.1038/ng.2666	2013	Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population.	BCL6
23852366	10.18632/oncotarget.1149	2013	STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL).	BCL6
23911289	10.1016/j.celrep.2013.06.016	2013	A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.	BCL6
23954399	10.1016/j.molimm.2013.07.001	2013	The zinc finger transcription factor ZXDC activates CCL2 gene expression by opposing BCL6-mediated repression.	BCL6
23974956	10.1038/ni.2688	2013	MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.	BCL6
24009228	10.1182/blood-2013-05-498329	2013	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.	BCL6
20981461	10.1007/s10006-010-0254-5	2012	Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin 'double-hit' lymphoma: report of a case.	BCL6
21788950	10.1038/leu.2011.189	2012	Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma.	BCL6
21804610	10.1038/onc.2011.331	2012	The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding.	BCL6
21855110	10.1016/j.humpath.2011.05.018	2012	Molecular and immunohistochemical characterization of B-cell lymphoma-2-negative follicular lymphomas.	BCL6
22113614	10.1038/nature10688	2012	FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.	BCL6
22124122	10.4049/jimmunol.1102297	2012	Wnt5a is secreted by follicular dendritic cells to protect germinal center B cells via Wnt/Ca2+/NFAT/NF-κB-B cell lymphoma 6 signaling.	BCL6
22204827	10.1016/j.cyto.2011.12.001	2012	Type I interferons directly down-regulate BCL-6 in primary and transformed germinal center B cells: differential regulation in B cell lines derived from endemic or sporadic Burkitt's lymphoma.	BCL6
22387553	10.4049/jimmunol.1102899	2012	Downregulation of inflammatory microRNAs by Ig-like transcript 3 is essential for the differentiation of human CD8(+) T suppressor cells.	BCL6
22395507		2012	Immunologic and cytogenetic markers expressed in non-Hodgkin lymphoma of head and neck.	BCL6
22451912	10.1073/pnas.1201168109	2012	PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas.	BCL6
22668559	10.1093/jb/mvs065	2012	Mediator CDK subunits are platforms for interactions with various chromatin regulatory complexes.	BCL6
22968395	10.1097/PDM.0b013e3182585c3c	2012	Frequencies of BCL2 and BCL6 translocations in representative Chinese follicular lymphoma patients: morphologic, immunohistochemical, and FISH analyses.	BCL6
22994707	10.7314/apjcp.2012.13.7.3037	2012	Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.	BCL6
23042398	10.3760/cma.j.issn.1003-9406.2012.05.017	2012	[Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].	BCL6
20830719	10.1002/ijc.25663	2011	BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.	BCL6
20966935	10.1038/leu.2010.230	2011	Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas.	BCL6
21390126	10.1038/nature09730	2011	Inactivating mutations of acetyltransferase genes in B-cell lymphoma.	BCL6
21424034		2011	B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.	BCL6
21623692	10.3109/10428194.2011.573032	2011	Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma.	BCL6
21783402	10.1016/j.oraloncology.2011.06.506	2011	Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas.	BCL6
21988858	10.1186/1746-1596-6-97	2011	Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas.	BCL6
22158496	10.1700/989.10724	2011	Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas.	BCL6
19797315	10.1093/jmcb/mjp032	2010	An expanding job description for bcl6.	BCL6
19797725	10.3324/haematol.2009.007203	2010	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.	BCL6
19925052	10.3109/10428190903370338	2010	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.	BCL6
20175752	10.1042/BJ20091578	2010	ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus.	BCL6
20299965	10.1097/QAD.0b013e328332d5b1	2010	Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study.	BCL6
20348878	10.1038/modpathol.2010.76	2010	Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas.	BCL6
20385356	10.1016/j.ccr.2010.03.012	2010	Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma.	BCL6
20385364	10.1016/j.ccr.2009.12.050	2010	A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.	BCL6
20557674	10.1179/102453309X12583347113573	2010	CD56-positive diffuse large B-cell lymphoma: possible association with extranodal involvement and bcl-6 expression.	BCL6
20630860	10.1074/jbc.M110.121459	2010	A novel mechanism involving coordinated regulation of nuclear levels and acetylation of NF-YA and Bcl6 activates RGS4 transcription.	BCL6
20733034	10.1084/jem.20100204	2010	DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas.	BCL6
21041953	10.1172/JCI42869	2010	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.	BCL6
21055028		2010	[Study on genetic aberrations of ocular mucosa-associated lymphoid tissue lymphomas occurring in southern China].	BCL6
21092586		2010	[Acquired somatic mutations in non-coding region of bcl-6 gene in germinal center-type diffuse large B-cell lymphoma].	BCL6
19236753		2009	[Expressions of bcl-6, lpp and miR-28 genes in diffuse large B cell lymphoma cell lines].	BCL6
19307668	10.1182/blood-2008-12-193037	2009	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.	BCL6
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	BCL6
19367498	10.1080/10428190902842626	2009	BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia.	BCL6
19448593	10.1038/modpathol.2009.73	2009	Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.	BCL6
19465899	10.1038/modpathol.2009.81	2009	t(14;18)-negative follicular lymphomas are associated with a high frequency of BCL6 rearrangement at the alternative breakpoint region.	BCL6
19525926	10.1038/modpathol.2009.87	2009	Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis.	BCL6
19549844	10.1073/pnas.0903854106	2009	BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.	BCL6
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	BCL6
19575892		2009	[Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified].	BCL6
19656156	10.1111/j.1349-7006.2009.01268.x	2009	Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.	BCL6
19701248	10.1038/onc.2009.230	2009	Functional interaction of HTLV-1 tax protein with the POZ domain of the transcriptional repressor BCL6.	BCL6
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	BCL6
19787248	10.3892/ijo_00000409	2009	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.	BCL6
19855081	10.1182/blood-2009-02-204362	2009	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.	BCL6
19966776	10.1038/nm.2059	2009	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.	BCL6
20032416		2009	BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2.	BCL6
20160358	10.4103/0973-1482.59901	2009	Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.	BCL6
17989715	10.1038/sj.leu.2405025	2008	T(3;7)(q27;q32) fuses BCL6 to a non-coding region at FRA7H near miR-29.	BCL6
17989722	10.1038/sj.leu.2404999	2008	Characterization of three t(3;8)(q27;q24) translocations from diffuse large B-cell lymphomas.	BCL6
18166802	10.3324/haematol.11927	2008	Chromosomal translocations involving BCL6 in MALT lymphoma.	BCL6
18203018	10.1080/10428190701742472	2008	Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features.	BCL6
18212045	10.1128/MCB.01400-07	2008	CtBP is an essential corepressor for BCL6 autoregulation.	BCL6
18256039	10.1093/intimm/dxn005	2008	Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6.	BCL6
18280243	10.1016/j.molcel.2007.12.026	2008	Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.	BCL6
18346918	10.1016/j.bcmd.2008.02.003	2008	BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.	BCL6
18354204	10.4049/jimmunol.180.7.4805	2008	STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation.	BCL6
18500267	10.1038/modpathol.2008.75	2008	BCL6 gene amplification/3q27 gain is associated with unique clinicopathological characteristics among follicular lymphoma without BCL2 gene translocation.	BCL6
18604721	10.1080/10428190802087447	2008	Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience.	BCL6
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	BCL6
18801072	10.1111/j.1440-1827.2008.02273.x	2008	Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia.	BCL6
19052359	10.1107/S1744309108036063	2008	Structure of the wild-type human BCL6 POZ domain.	BCL6
16815642	10.1016/j.patbio.2006.04.001	2007	The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.	BCL6
16819511	10.1038/sj.onc.1209775	2007	STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.	BCL6
17151114	10.1128/JVI.01822-06	2007	EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.	BCL6
17210865	10.1182/blood-2006-07-038000	2007	BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?	BCL6
17296585	10.3324/haematol.10682	2007	MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes.	BCL6
17360630	10.1073/pnas.0611399104	2007	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.	BCL6
17468402	10.1073/pnas.0701770104	2007	Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas.	BCL6
17476282	10.1038/sj.leu.2404706	2007	Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin.	BCL6
17542409	10.1177/147323000703500206	2007	BCL6 gene mutations in transitional cell carcinomas.	BCL6
17545502	10.1182/blood-2007-01-069575	2007	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.	BCL6
17558410	10.1038/ni1478	2007	Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.	BCL6
17576390	10.1111/j.1365-2893.2006.00833.x	2007	Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases.	BCL6
17625604	10.1038/sj.leu.2404856	2007	Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.	BCL6
17635238	10.1111/j.1600-0609.2007.00892.x	2007	Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.	BCL6
17785208	10.1016/j.ccr.2007.08.011	2007	A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.	BCL6
17889713	10.1016/j.cancergencyto.2007.06.003	2007	Diffuse large B-cell lymphoma with a novel translocation involving BCL6.	BCL6
16125304	10.1016/j.canlet.2005.07.015	2006	Single nucleotide polymorphism in 5'-flanking region of BCL6 is not associated with increased risk of non-Hodgkin's lymphoma.	BCL6
16249378	10.1182/blood-2005-04-1629	2006	BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma.	BCL6
16489068	10.1158/1078-0432.CCR-05-1699	2006	Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.	BCL6
16704730	10.1186/1476-4598-5-18	2006	Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.	BCL6
16728698	10.1182/blood-2006-03-011536	2006	Association of Ig/BCL6 translocations with germinal center B lymphocytes in human lymphoid tissues: implications for malignant transformation.	BCL6
16733207	10.1016/j.humpath.2006.01.018	2006	BCL6 alternative breakpoint region break and homozygous deletion of 17q24 in the nodular lymphocyte predominance type of Hodgkin's lymphoma-derived cell line DEV.	BCL6
16772602	10.1182/blood-2006-05-022517	2006	High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma.	BCL6
16773719	10.3748/wjg.v12.i22.3602	2006	Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease.	BCL6
16896311	10.1097/01.jnen.0000229988.48042.ae	2006	Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination.	BCL6
15609396	10.3748/wjg.v11.i1.51	2005	Point mutation of 5' noncoding region of BCL-6 gene in primary gastric lymphomas.	BCL6
16094416	10.1038/sj.leu.2403915	2005	Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma.	BCL6
16147992	10.1074/mcp.M500112-MCP200	2005	Analysis of BCL6-interacting proteins by tandem mass spectrometry.	BCL6
16194898	10.1080/10428190500125648	2005	Translocation of BCL2 and BCL6 to the same immunoglobulin heavy chain locus in a case of follicular lymphoma.	BCL6
16264183	10.1093/jnci/dji344	2005	A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma.	BCL6
14551142	10.1182/blood-2003-06-2081	2004	ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.	BCL6
15024721	10.14670/HH-19.637	2004	Pathogenetic role of BCL6 translocation in B-cell non-Hodgkin's lymphoma.	BCL6
15191563	10.1111/j.0022-202X.2004.22720.x	2004	Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas.	BCL6
15277222	10.1016/S0002-9440(10)63313-5	2004	Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.	BCL6
15339680		2004	Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin's lymphoma.	BCL6
15377470		2004	Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.	BCL6
15531890	10.1038/nm1134	2004	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.	BCL6
15577913	10.1038/nature03147	2004	The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.	BCL6
12393409	10.1182/blood-2002-05-1592	2003	Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma.	BCL6
12507907	10.1016/s0002-9440(10)63815-1	2003	Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins.	BCL6
12515714	10.1182/blood-2002-11-3387	2003	Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.	BCL6
12555064	10.1038/sj.onc.1206152	2003	Ambivalent role of BCL6 in cell survival and transformation.	BCL6
12562237	10.5858/2003-127-208-EOPMOB	2003	Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.	BCL6
12775568	10.1182/blood-2002-12-3630	2003	Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma.	BCL6
12835729	10.1038/sj.leu.2402997	2003	The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene.	BCL6
12860928	10.1084/jem.20021395	2003	BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells.	BCL6
12879322	10.1007/s00240-003-0324-3	2003	The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium.	BCL6
12881702	10.1038/sj.onc.1206755	2003	BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells.	BCL6
14654791	10.1038/sj.onc.1206995	2003	Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha).	BCL6
14655758	10.1111/j.1750-3639.2003.tb00483.x	2003	Molecular characterization of BCL6 breakpoints in primary diffuse large B-cell lymphomas of the central nervous system identifies GAPD as novel translocation partner.	BCL6
14690607	10.1016/s1097-2765(03)00454-4	2003	Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.	BCL6
15202519	10.1080/10428190310001621588	2003	Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6.	BCL6
11821949	10.1038/sj.onc.1205099	2002	The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.	BCL6
11854457	10.1073/pnas.042702599	2002	The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis.	BCL6
11914273	10.1101/gad.929302	2002	A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.	BCL6
11929873	10.1074/jbc.M201736200	2002	Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor.	BCL6
12165517	10.4049/jimmunol.169.4.1922	2002	Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene.	BCL6
12217802		2002	Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.	BCL6
12389616	10.1080/10428190290033305	2002	Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications.	BCL6
12402037	10.1038/ng1018	2002	Acetylation inactivates the transcriptional repressor BCL6.	BCL6
12469325	10.1002/hon.689	2002	The proto-oncogene BCL-6 in normal and malignant B cell development.	BCL6
12477975		2002	Transcriptional regulation of the BCL-6 gene: mechanistic dissection using mutant cell lines.	BCL6
11911418	10.3109/10428190109097762	2001	A polymorphism in the BCL-6 gene is associated with follicle center lymphoma.	BCL6
10898795		2000	BCoR, a novel corepressor involved in BCL-6 repression.	BCL6
11175338	10.1038/sj.onc.1203976	2000	Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF.	BCL6
11920179	10.1038/sj.thj.6200002	2000	FISH analysis with a YAC probe improves detection of LAZ3/BCL6 rearrangement in non-Hodgkin's lymphoma.	BCL6
10490843	10.1038/sj.onc.1202892	1999	Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci.	BCL6
10611298	10.1073/pnas.96.26.14831	1999	Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.	BCL6
9649500	10.1101/gad.12.13.1953	1998	Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor.	BCL6
9047392	10.1038/sj.onc.1200903	1997	Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation.	BCL6
9110977	10.1126/science.276.5312.589	1997	Control of inflammation, cytokine expression, and germinal center formation by BCL-6.	BCL6
9171827	10.1038/ng0697-161	1997	The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation.	BCL6
9380707	10.1073/pnas.94.20.10762	1997	Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.	BCL6
8692924	10.1073/pnas.93.14.6947	1996	BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.	BCL6
8758205	10.1002/(SICI)1096-9896(199606)179:2&lt;145::AID-PATH565&gt;3.0.CO;2-1	1996	BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas.	BCL6
7639334		1995	A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells.	BCL6
7795234		1995	BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts.	BCL6
7795255		1995	BCL-6 protein is expressed in germinal-center B cells.	BCL6
8618933	10.1073/pnas.92.26.12520	1995	Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma.	BCL6
8057668		1994	The organization of the BCL6 gene.	BCL6
8274736		1994	Molecular cloning of the breakpoint for 3q27 translocation in B-cell lymphomas and leukemias.	BCL6
8274740		1994	Gene involved in the 3q27 translocation associated with B-cell lymphoma, BCL5, encodes a Krüppel-like zinc-finger protein.	BCL6
8220427	10.1038/ng0993-66	1993	LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas.	BCL6
8235596	10.1126/science.8235596	1993	Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma.	BCL6
8506375	10.1073/pnas.90.11.5262	1993	Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas.	BCL6
